A detailed history of Natixis Advisors, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 29,327 shares of NBIX stock, worth $3.68 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,327
Previous 35,260 16.83%
Holding current value
$3.68 Million
Previous $4.85 Million 30.39%
% of portfolio
0.01%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$114.58 - $153.15 $679,803 - $908,638
-5,933 Reduced 16.83%
29,327 $3.38 Million
Q2 2024

Aug 01, 2024

BUY
$130.86 - $143.19 $462,066 - $505,603
3,531 Added 11.13%
35,260 $4.85 Million
Q1 2024

Apr 25, 2024

BUY
$130.4 - $143.74 $247,499 - $272,818
1,898 Added 6.36%
31,729 $4.38 Million
Q4 2023

Feb 06, 2024

SELL
$106.07 - $132.76 $54,307 - $67,973
-512 Reduced 1.69%
29,831 $3.93 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $523,973 - $652,598
5,573 Added 22.5%
30,343 $3.41 Million
Q2 2023

Aug 15, 2023

SELL
$89.53 - $104.87 $2.64 Million - $3.09 Million
-29,481 Reduced 54.34%
24,770 $2.34 Million
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $653,217 - $853,881
-6,941 Reduced 11.34%
54,251 $5.49 Million
Q4 2022

Jan 27, 2023

SELL
$106.72 - $127.06 $989,294 - $1.18 Million
-9,270 Reduced 13.16%
61,192 $7.31 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $337,474 - $395,339
3,667 Added 5.49%
70,462 $7.48 Million
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $488,542 - $645,051
6,446 Added 10.68%
66,795 $6.51 Million
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $2.37 Million - $3.1 Million
32,746 Added 118.63%
60,349 $5.66 Million
Q4 2021

Feb 08, 2022

SELL
$79.65 - $106.22 $1.07 Million - $1.43 Million
-13,419 Reduced 32.71%
27,603 $2.35 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $507,600 - $583,286
5,890 Added 16.77%
41,022 $3.93 Million
Q2 2021

Aug 12, 2021

BUY
$89.43 - $102.27 $97,836 - $111,883
1,094 Added 3.21%
35,132 $3.42 Million
Q1 2021

May 05, 2021

BUY
$87.57 - $119.4 $319,980 - $436,287
3,654 Added 12.03%
34,038 $3.31 Million
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $315,657 - $393,454
-3,632 Reduced 10.68%
30,384 $2.91 Million
Q3 2020

Nov 12, 2020

BUY
$96.16 - $135.15 $1.83 Million - $2.57 Million
19,003 Added 126.58%
34,016 $3.27 Million
Q2 2020

Aug 11, 2020

BUY
$85.09 - $130.36 $37,950 - $58,140
446 Added 3.06%
15,013 $1.83 Million
Q1 2020

Apr 27, 2020

BUY
$75.11 - $113.76 $211,359 - $320,120
2,814 Added 23.94%
14,567 $1.26 Million
Q4 2019

Feb 10, 2020

BUY
$86.8 - $118.57 $98,518 - $134,576
1,135 Added 10.69%
11,753 $1.26 Million
Q3 2019

Nov 12, 2019

BUY
$83.82 - $101.5 $890,000 - $1.08 Million
10,618 New
10,618 $957,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.